[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE2013C029I2 - - Google Patents

Info

Publication number
BE2013C029I2
BE2013C029I2 BE2013C029C BE2013C029C BE2013C029I2 BE 2013C029 I2 BE2013C029 I2 BE 2013C029I2 BE 2013C029 C BE2013C029 C BE 2013C029C BE 2013C029 C BE2013C029 C BE 2013C029C BE 2013C029 I2 BE2013C029 I2 BE 2013C029I2
Authority
BE
Belgium
Prior art keywords
macular degeneration
diabetic retinopathy
related macular
chimeric polypeptides
including age
Prior art date
Application number
BE2013C029C
Other languages
French (fr)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BE2013C029I2 publication Critical patent/BE2013C029I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)

Abstract

Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
BE2013C029C 1999-06-08 2013-05-13 BE2013C029I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (1)

Publication Number Publication Date
BE2013C029I2 true BE2013C029I2 (en) 2019-03-06

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C029C BE2013C029I2 (en) 1999-06-08 2013-05-13

Country Status (32)

Country Link
EP (2) EP1183353B1 (en)
JP (2) JP4723140B2 (en)
KR (1) KR100659477B1 (en)
CN (3) CN101433715B (en)
AT (2) ATE417928T1 (en)
AU (2) AU779303B2 (en)
BE (1) BE2013C029I2 (en)
BR (2) BRPI0011407B8 (en)
CA (1) CA2376379C (en)
CY (2) CY1108883T1 (en)
CZ (2) CZ302689B6 (en)
DE (2) DE60041159D1 (en)
DK (2) DK1544299T3 (en)
ES (2) ES2319305T3 (en)
FR (1) FR13C0028I2 (en)
HR (1) HRP20010908B1 (en)
HU (3) HU229156B1 (en)
IL (3) IL146890A0 (en)
LT (1) LTC1183353I2 (en)
LU (1) LU92195I2 (en)
ME (2) MEP3208A (en)
MX (1) MXPA01012630A (en)
NO (4) NO330775B1 (en)
NZ (1) NZ515913A (en)
PL (1) PL208247B1 (en)
PT (2) PT1544299E (en)
RS (1) RS50073B (en)
RU (1) RU2265661C2 (en)
SK (1) SK287332B6 (en)
UA (1) UA74146C2 (en)
WO (1) WO2000075319A1 (en)
ZA (1) ZA200110068B (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
JP4669984B2 (en) 2001-01-19 2011-04-13 ベジェニクス リミテッド F1t4 (VEGFR-3) and antitumor therapy as a target for tumor imaging
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
ATE500842T1 (en) 2002-05-04 2011-03-15 Acorda Therapeutics Inc COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL GROWTH
PL1608685T3 (en) * 2003-03-28 2007-07-31 Regeneron Pharma Vegf antagonists for the treatment of diabetes
EP2354155B1 (en) * 2003-05-16 2017-05-03 Acorda Therapeutics, Inc. Fusion Proteins for Treatment of CNS
MXPA05012307A (en) 2003-05-16 2006-07-03 Acorda Therapeutics Inc Proteoglycan degrading mutants for treatment of cns.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US7300653B2 (en) 2003-05-28 2007-11-27 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1631317A2 (en) * 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (en) 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
EP1653992A1 (en) * 2003-08-06 2006-05-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
JP4926962B2 (en) 2004-05-18 2012-05-09 アコーダ セラピューティクス、インク． Purification method of chondroitinase and its stable preparation
ATE548384T1 (en) 2004-06-08 2012-03-15 Chengdu Kanghong Biotechnologies Co Ltd A CHIMERIC PROTEIN INHIBITING ANGIOGENESIS AND USE THEREOF
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
AU2005265071A1 (en) * 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
CA2567795C (en) 2004-07-30 2013-06-11 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
BRPI0515264B1 (en) 2004-09-13 2018-12-18 Genzyme Corp fusion protein according to formula x-y-z, composition, nucleic acid molecule, its uses and multimerization method of a polypeptide x
FR2878749B1 (en) * 2004-12-03 2007-12-21 Aventis Pharma Sa ANTITUMOR COMBINATIONS CONTAINING IN VEGT INHIBITOR AGENT AND 5FU OR ONE OF ITS DERIVATIVES
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
US20060217311A1 (en) 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
JP5189985B2 (en) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． Composition using chondroitinase ABCI mutant and method of using the same
JP5489465B2 (en) † 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Method of treating tumor growth inhibition with a Dll4 antagonist
FR2895258B1 (en) 2005-12-22 2008-03-21 Aventis Pharma Sa COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (en) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Application of VEGF receptor fusion protein in the treatment of eye diseases
HUE053612T2 (en) 2006-06-16 2021-07-28 Regeneron Pharma Vegf antagonist formulations suitable for intravitreal administration
NZ576404A (en) 2006-09-29 2012-02-24 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer involving dll4
EP2450442B1 (en) 2006-10-10 2017-07-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (en) * 2007-07-05 2010-10-22 Aventis Pharma Sa ANTITUMOR COMBINATIONS CONTAINING A VEGF INHIBITOR AGENT AND IRINOTECAN
CN101575379B (en) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 Soluble VEGFR (vascular endothelial growth factor receptor) difunctional fusion receptor as well as preparation method and application thereof
ES2836948T3 (en) 2008-11-03 2021-06-28 Molecular Partners Ag Binding proteins that inhibit VEGF-A receptor interaction
CN101838329A (en) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 Anti-angiogenesis fusion protein
PL3072526T3 (en) 2009-10-16 2019-04-30 Oncomed Pharm Inc Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
TWI510246B (en) * 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
LT2601214T (en) 2010-08-06 2018-02-26 Genzyme Corporation Vegf antagonist compositions and uses thereof
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
EP4360709A3 (en) 2011-01-13 2024-07-03 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
KR101397088B1 (en) 2011-06-10 2014-05-19 강원대학교산학협력단 A fusion protein for inhibiting both angiogenesis and tumor cell proliferation, and composition comprising the same
JO3370B1 (en) * 2011-11-10 2019-03-13 Regeneron Pharma Methods of inhibiting tumor growth by antagonizing il-6 receptor
DK2785744T3 (en) * 2011-12-01 2017-11-27 Innovent Biologics Inc PROTEIN INHIBITORS FOR COMPLEMENT AND VEGF PATHWAYS AND PROCEDURES FOR USE THEREOF
CN103304668B (en) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap immune fusion protein, its preparation method and application thereof
DK2846836T3 (en) 2012-05-07 2019-11-11 Allergan Inc PROCEDURE FOR TREATMENT OF AMD WITH PATIENTS REFRACHRANT ABOUT ANTI-VEGF THERAPY
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (en) 2012-11-14 2015-06-10 Regeneron Pharma METHODS TO TREAT OVARY CANCER WITH DLL4 ANTAGONISTS
PL2956476T4 (en) 2013-02-18 2020-09-21 Vegenics Pty Limited Ligand binding molecules and uses thereof
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
CN104193828B (en) * 2013-09-12 2017-04-05 北京韩美药品有限公司 The recombination fusion protein of HER2 and VEGFR signal paths is blocked simultaneously
DK3065761T3 (en) 2013-11-05 2020-02-17 Allergan Inc PROCEDURE FOR TREATING THE EYES OF THE EYE WITH AN ANTI-VEGF DARPIN
WO2015173260A1 (en) 2014-05-12 2015-11-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
RS58957B1 (en) 2014-07-18 2019-08-30 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
JP2016036322A (en) * 2014-08-11 2016-03-22 日本化薬株式会社 Chimeric proteins that bind to angiogenic factors
PL3230316T3 (en) 2014-12-11 2022-05-02 Bayer Healthcare Llc Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202440904A (en) 2015-08-04 2024-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (en) * 2015-10-15 2019-01-08 (주)알테오젠 Method for manufacturing fusion proteins with IgG Fc domain
WO2017065559A1 (en) 2015-10-15 2017-04-20 (주)알테오젠 Method for producing fusion protein having igg fc domain
WO2017087798A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
MX382662B (en) 2015-11-18 2025-03-11 Sio2 Medical Products Inc PHARMACEUTICAL PACKAGING FOR OPHTHALMIC FORMULATIONS.
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
HRP20231379T1 (en) 2015-12-03 2024-02-16 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
JPWO2018070390A1 (en) 2016-10-12 2019-08-22 第一三共株式会社 Composition comprising anti-ROBO4 antibody and other agent
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
TW201904610A (en) 2017-06-14 2019-02-01 德商拜耳製藥公司 Non-antibody vegf antagonists for the treatment of neovascular glaucoma
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
CN111344410B (en) 2017-08-17 2023-09-15 济世易为生物有限公司 Method for purifying glycosylated proteins from host cell galectins and other contaminants
CN111356471A (en) 2017-11-20 2020-06-30 济世发展生物药业有限公司 Abutip formulation comprising lysine salt as tonicity modifier and use thereof
DK3717636T5 (en) * 2017-11-27 2024-08-26 4D Molecular Therapeutics Inc Adeno-associated-virus variant capsids and use in inhibiting angiogenesis
PT3716992T (en) 2017-11-30 2022-08-31 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
KR102751947B1 (en) 2017-12-13 2025-01-09 리제너론 파아마슈티컬스, 인크. Device and system for managing chromatography column bed support, and related methods
KR20200112893A (en) 2018-01-26 2020-10-05 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Methods and compositions for treating angiogenic disorders using anti-VEGF agents
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3099551A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (en) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 Antibody fusion protein, preparation method and application thereof
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
TW202123988A (en) 2019-09-03 2021-07-01 美商安進公司 Injection device for drug delivery and packaging for the injection device
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders
MX2022006241A (en) 2019-11-25 2022-08-22 Univ California Long-acting vegf inhibitors for intraocular neovascularization.
CA3163876A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and methods of use thereof
CN114401994A (en) 2019-12-06 2022-04-26 瑞泽恩制药公司 Anti-VEGF protein composition and preparation method thereof
WO2021173603A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
JP2023525034A (en) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド VEGF traps and minitraps and methods of treating eye disorders and cancer
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
US20250002557A1 (en) 2021-11-24 2025-01-02 Suzhou Light Ferry Biomed. Co., Ltd Multi-specific ligand-binding molecules and applications thereof
CN119677771A (en) * 2022-08-02 2025-03-21 帕诺洛斯生物科技有限公司 Modified fusion protein and its use
CN119584953A (en) 2022-09-16 2025-03-07 齐鲁制药有限公司 A stable high-concentration self-buffered pharmaceutical composition
WO2025033876A1 (en) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 Conjugate of modified fusion protein and scfv, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
HRP20010908B1 (en) 2006-05-31
IL190234A0 (en) 2008-11-03
CN101433715B (en) 2013-04-17
HUP0201515A2 (en) 2002-08-28
ES2319305T3 (en) 2009-05-06
NZ515913A (en) 2004-01-30
EP1544299A1 (en) 2005-06-22
ME00024B (en) 2010-02-10
AU2005201365A1 (en) 2005-04-28
YU86901A (en) 2004-05-12
CZ20014387A3 (en) 2002-10-16
IL146890A0 (en) 2002-08-14
WO2000075319A1 (en) 2000-12-14
DE60041159D1 (en) 2009-01-29
HUP0201515A3 (en) 2004-12-28
NO20016036L (en) 2002-02-08
PT1183353E (en) 2005-06-30
PT1544299E (en) 2009-03-18
RU2265661C2 (en) 2005-12-10
MEP3208A (en) 2010-02-10
KR100659477B1 (en) 2006-12-20
CN103349781B (en) 2015-04-01
PL352246A1 (en) 2003-08-11
JP5273746B2 (en) 2013-08-28
LTPA2013009I1 (en) 2013-06-25
ATE293164T1 (en) 2005-04-15
ZA200110068B (en) 2002-12-06
BRPI0011407B8 (en) 2021-05-25
HU229156B1 (en) 2013-09-30
HK1185798A1 (en) 2014-02-28
HK1043388A1 (en) 2002-09-13
HU230159B1 (en) 2015-09-28
AU5040400A (en) 2000-12-28
DK1183353T3 (en) 2005-08-08
EP1544299B1 (en) 2008-12-17
CY2013019I1 (en) 2015-11-04
EP1183353A1 (en) 2002-03-06
SK17522001A3 (en) 2003-04-01
FR13C0028I2 (en) 2014-05-16
JP4723140B2 (en) 2011-07-13
CN103349781A (en) 2013-10-16
IL146890A (en) 2008-07-08
NO20100656L (en) 2002-02-08
DE60019415D1 (en) 2005-05-19
HRP20010908A2 (en) 2005-04-30
CA2376379A1 (en) 2000-12-14
NO330775B1 (en) 2011-07-11
CY2013019I2 (en) 2015-11-04
DK1544299T3 (en) 2009-03-23
AU2005201365B2 (en) 2007-08-09
KR20020019070A (en) 2002-03-09
ATE417928T1 (en) 2009-01-15
JP2011024595A (en) 2011-02-10
LTC1183353I2 (en) 2023-02-27
FR13C0028I1 (en) 2013-06-14
RS50073B (en) 2009-01-22
JP2003501089A (en) 2003-01-14
NO2013010I1 (en) 2013-06-17
CZ302689B6 (en) 2011-09-07
CN100523187C (en) 2009-08-05
NO20016036D0 (en) 2001-12-10
PL208247B1 (en) 2011-04-29
CN101433715A (en) 2009-05-20
LU92195I2 (en) 2013-07-15
BRPI0011407B1 (en) 2018-09-25
UA74146C2 (en) 2005-11-15
CN1369009A (en) 2002-09-11
HK1132653A1 (en) 2010-03-05
ES2237429T3 (en) 2005-08-01
BR0011407A (en) 2002-04-02
CZ303656B6 (en) 2013-01-30
AU779303B2 (en) 2005-01-13
HUS1300052I1 (en) 2016-08-29
SK287332B6 (en) 2010-07-07
CA2376379C (en) 2007-08-07
EP1183353B1 (en) 2005-04-13
MXPA01012630A (en) 2002-07-22
NO2013010I2 (en) 2013-05-15
NO332559B1 (en) 2012-10-29
NO2022060I1 (en) 2022-12-21
CY1108883T1 (en) 2014-07-02
DE60019415T2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
BE2013C029I2 (en)
DE60124710D1 (en) ANALOG OF GLUCAGON SIMILAR PEPTIDE-1
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
AU6110301A (en) Diagnostics and therapeutics for macular degeneration-related disorders
MXPA02001911A (en) Human ctla 4 antibodies and their uses.
TR200100754T2 (en) Serotonergic 5HT2 for treating glaucoma.
ATE396738T1 (en) USE OF GLP-2 PEPTIDES
IL153554A (en) Methods and compositions utilizing quinazolinones
AU3209700A (en) Corneal microjet cutter with adjustable applanation template
EP1077063A3 (en) Methods for treating skin pigmentation
PL1694354T3 (en) Method for preventing and treating diabetes using neurturin
AU4128901A (en) Colored visco-elastic composition
AU2001259775A1 (en) Method for treating retinal degeneration with purinergic receptor agonists
AU5977501A (en) Method for treating retinal degeneration with purinergic receptor agonists
EP1351968A4 (en) "ALPHA1 UNIT OF THE SODIUM CHANNEL, POLYPEPTIDES THEREOF AND THEIR USE FOR THE TREATMENT OF GENERALIZED EPILEPSY WITH FEVERING SEVERE SEVERIES."
HUP0204177A3 (en) N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
ZA200309642B (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia.
AU3037000A (en) Agents for treating textiles, method for producing them and their use
EP1371732A4 (en) Fused protein having beta 1,2-n-acetylglucosaminyltransferase ii activity and process for producing the same
WO2003028651A3 (en) Antipsychotic agents stimulate neurogenesis in brain
ZA200203589B (en) Concomitant drugs for treating glaucoma.
SI1459750T1 (en) (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders